Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Flemish agency for Innovation by Science and Technology (IWT) has awarded EUR2.7m grant to Galapagos for antibacterial research.
Subscribe to our email newsletter
The project that is scheduled for three years and is being funded by IWT, will focus on advancing the development of the company’s candidate drug targeting DNA pol III alpha (DnaE).
Company’s candidate drug previously demonstrated efficacy against several drug resistant Staphylococcus aureus species including Methicillin-resistant Staphylococcus aureus.
The grant will support the development of the anti-bacterial candidate to identify new antibiotic treatments targeting additional bacterial species.
Galapagos CSO Dr Piet Wigerinck said, "With this grant, we can support the search for more novel inhibitors of the antibacterial target DNA pol III alpha to fight against these difficult-to-treat bacterial species."
Company will collaborate with researchers of Ghent University and the Free University Brussels for the project.
The candidate drug targeting DNA pol III alpha works by inhibiting the activity of DnaE a bacterial protein that plays a vital role in self reproduction.